Stille AB

Stille AB is a Swedish-headquartered company, operating globally, that specializes in the design, manufacture, and sale of surgical instruments. Their extensive portfolio of medical tools encompasses a wide variety of items such as specialized forceps (including artery, ligature, wire twisting, and general types), bone-cutting instruments like cutters and rongeurs, various clamps, curettes, raspatories, elevators, needle holders, micro instruments, osteotomes, chisels, retractors, skin hooks, and scissors. Additionally, they provide C-arm tables. These products are essential for a broad range of surgical disciplines, including ERCP/abdominal fluoroscopy, neuro/spine, pain management, urology, and vascular surgeries, as well as general open surgical procedures. Beyond product provision, Stille also offers crucial post-sales support services, such as instrument repair, routine maintenance, and thorough inspections. The company leverages strategic partnerships, notably a collaboration agreement with GE Healthcare and a distribution arrangement with Synovis Micro. Its sales strategy involves direct customer engagement, distribution networks, and supply to OEM manufacturers of C-frame systems. Founded in 1841 and headquartered in Torshälla, Sweden, Stille AB operates as a subsidiary of Linc AB.

Stille AB trades as STIL.ST on STO. The company is classified in Healthcare / Medical - Devices and reports in SEK.

The current profile places the business in Medical - Devices. This section is intended to summarize the operating segments, products, geographies, and main revenue lines from official filings.

Detailed operating-segment data is not available for this symbol yet.

Use this area for management strategy, capital allocation priorities, target markets, and measurable goals from the latest annual report or investor presentation.

The app now provides the structure, but exact strategic claims should come from official company documents before being treated as a finished investment thesis.

Stille AB can be compared against peers such as BICO Group AB (publ), BioInvent International AB (publ), C-Rad AB (publ), Diamyd Medical AB (publ), Genovis AB (publ.), Humana AB (publ).

A complete thesis should compare growth, margins, balance-sheet risk, valuation multiples, and market position against direct competitors.

Current signals to investigate include market capitalization of $2.40B, beta of 0.39, and return on equity of N/A.

This section should be validated with evidence such as durable margins, brand strength, regulation, switching costs, cost advantage, distribution, or technology.

Key risks should include financial leverage, cyclicality, customer concentration, regulatory exposure, currency risk, and execution risk.

STIL.ST currently shows total debt of N/A and beta of 0.39. Missing data should be treated as a research gap, not as low risk.

Production-capacity detail is not available as structured data yet. For industrial, defense, semiconductor, or real-estate companies, this should be reviewed from annual reports and investor presentations.

No structured backlog field is available yet. If the company reports backlog, review the relevant filing section before adding it to the thesis.

Use this section for major contracts, product launches, construction projects, acquisitions, or strategic programs that can materially affect valuation.

No recent SEC-style filings are available for this symbol yet.

Customer concentration is not available as structured data here. Add it from official filings when a company discloses material customers or revenue concentration.

Supplier concentration and critical supply-chain dependencies are not available as structured data here. This should be researched from annual reports and risk disclosures.

Company website: https://www.stille.se

For US-listed stocks, verify the thesis against official filings, earnings call transcripts, and company investor relations materials.